Aeglea Biotherapeutics shares owned by Jpmorgan Chase & Co
Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Jpmorgan Chase & Co
from 13F filings
Historical chart of Jpmorgan Chase & Co investment in Aeglea Biotherapeutics
Tip: Access up to 7 years of quarterly data
All positions including Aeglea Biotherapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Quarterly reported holdings in Aeglea Biotherapeutics by Jpmorgan Chase & Co
Quarter filed | Position value | Share count | Share price at filing |
---|---|---|---|
2024-12-31 | $821k | 35k | 23.28 |
2024-09-30 | $867k | 30k | 29.41 |
2024-06-30 | $535k | 23k | 23.51 |
2024-03-31 | $417 | 11 | 37.91 |
2023-12-31 | $882 | 41 | 21.51 |
2023-09-30 | $501 | 41 | 12.24 |